ArticleOncoscience2026
The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma.
Article in Oncoscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The MAPK and PI3K/AKT pathways are important components in cell growth and proliferation, which, when activated, result in cancer formation. Molecular alterations are the main cause of activation of the MAPK and PI3K/AKT pathways in the development of papillary thyroid carcinoma (PTC), the most common endocrine cancer. Activation of the MAPK pathway is usually caused by mutations in the BRAF, RAS, RET/PTC, and NTRK genes, while the activation of the PI3K/AKT pathway results from alterations in the PIK3CA, PTEN, and AKT genes. Moreover, hyperactivation of the MAPK pathway can be caused by overexpression of RTKs, GPCRs, and mutation in PTEN. Interactions between the two signaling pathways exacerbate tumor aggressiveness, dedifferentiation, radioiodine resistance, and response to targeted therapy in PTC. Recent developments in personalized medicine, including the introduction of new molecular diagnostic tools and targeted agents, have made considerable progress in the risk stratification and treatment strategies for papillary thyroid carcinoma. The current article reviews molecular mechanisms of activation of MAPK and PI3K/AKT pathways, their interaction, clinicopathological importance, and targeted treatments in papillary thyroid carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.